Search results for "acting"

showing 10 items of 338 documents

2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint.

2021

Abstract Aim The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide from 2014, but in 2019 an update was published. Based on this algorithm, a Working Group (WG), including ESCEO members and Chinese experts, wished to see how the new ESCEO algorithm was perceived by Chinese experts in knee OA and how it was integrated into their clinical practice. Methods A WG was held between members of the international ESCEO task force and a group of Chinese experts. Results Non-pharmacological approach should be combined with pharmacological interventions. …

AgingChinaSymptomatic slow-acting drugs for osteoarthritisOsteoarthritis03 medical and health sciences0302 clinical medicineMedicineHumans030212 general & internal medicineKnee osteoartrhitis · Patented crystalline glucosamine sulfate · Symptomatic slow-acting drugs for osteoarthritis · Algorithm · ChinaConsensus Document030203 arthritis & rheumatologyGlucosamineKnee osteoartrhitisbusiness.industryGeriatrics gerontologyTask forceAnti-Inflammatory Agents Non-SteroidalChondroitin SulfatesPatented crystalline glucosamine sulfateOsteoarthritis Kneemedicine.diseaseClinical PracticeAlgorithmPharmacological interventionsGeriatrics and GerontologybusinessAlgorithmAlgorithmsAging clinical and experimental research
researchProduct

Prescription-grade crystalline glucosamine sulfate as an add-on therapy to conventional treatments in erosive osteoarthritis of the hand: results fro…

2022

Abstract Objective To evaluate the efficacy of prescription-grade Crystalline Glucosamine Sulfate (pCGS) as an add-on treatment to conventional therapy, compared to usual therapy alone, in patients with erosive osteoarthritis of the hand (EHOA). Methods This 6-month retrospective case–control study included patients with concomitant knee osteoarthritis and symptomatic EHOA. Participants were stratified into two groups based on whether or not pCGS (1500 mg/day) was added to the conventional therapy (education and training in ergonomic principles, exercise and use on-demand of symptomatic drugs) for hand osteoarthritis. Patients were evaluated at baseline, after 3 and 6 months. Primary outcom…

AgingGlucosamineSymptomatic slow-acting drugs for osteoarthritisPainOsteoarthritis KneePrescription-grade crystalline glucosamine sulfateErosive hand osteoarthritis; Hand osteoarthritis; Pain; Prescription-grade crystalline glucosamine sulfate; Retrospective study; Symptomatic slow-acting drugs for osteoarthritisErosive hand osteoarthritisRetrospective studyPrescriptionsTreatment OutcomeCase-Control StudiesHand osteoarthritisHumansErosive hand osteoarthritis Hand osteoarthritis Pain Prescription-grade crystalline glucosamine sulfate Retrospective study Symptomatic slow-acting drugs for osteoarthritisGeriatrics and GerontologyRetrospective StudiesAging clinical and experimental research
researchProduct

2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint

2021

Abstract Background Since 2014, the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide. Aim Based on this document, a Southeast Asia Working Group (SEAWG) wished to see how the new ESCEO algorithm developed in 2019 was perceived by Southeast Asian experts and how it was integrated into their clinical practice. Methods A SEAWG was set up between members of the international ESCEO task force and a group of Southeast Asian experts. Results Non-pharmacological management should always be combined with pharmacological management. In step 1, symptoma…

AgingSymptomatic slow-acting drugs for osteoarthritisPharmacological managementOsteoarthritisSoutheast asianSoutheast asia03 medical and health sciences0302 clinical medicineMedicine and Health SciencesHumansMedicine030212 general & internal medicineLimited evidenceConsensus DocumentReimbursement030203 arthritis & rheumatologyGlucosamineKnee osteoartrhitisbusiness.industryTask forceAnti-Inflammatory Agents Non-SteroidalChondroitin SulfatesPatented crystalline glucosamine sulfateOsteoarthritis KneeKnee osteoartrhitis · Patented crystalline glucosamine sulfate · Symptomatic slow-acting drugs for osteoarthritis · Algorithmmedicine.diseaseAlgorithmClinical PracticeGeriatrics and GerontologybusinessAlgorithmAlgorithms
researchProduct

The In Vitro Pharmacological Profile Of LAS100977 - A Potent, Selective And Long-acting Beta-2 Receptor Agonist

2010

AgonistLong acting betabusiness.industrymedicine.drug_classMedicineInverse agonistSelective receptor modulatorPharmacologyReceptorbusinessPartial agonistIn vitroD34. NOVEL THERAPEUTIC OPTIONS IN AIRWAYS DISEASE
researchProduct

Pretreatment with gonadotropin-releasing hormone (GnRH) antagonists to prevent the flare-up effect of long-acting GnRH agonists: results of a pilot s…

2007

This study evaluated in vivo whether the flare-up effect of GnRH agonists can be suppressed through pretreatment with a GnRH antagonist. The classic flare-up effect caused by 3.8 mg goserelin acetate could not be suppressed through pretreatment using a single dosage of 3.24 mg cetrorelix acetate.

AgonistMaleendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classPilot ProjectsGonadotropin-releasing hormoneGonadotropin-Releasing HormoneHormone AntagonistsIn vivoInternal medicinemedicineFlare upHumansTestosteroneEstradiolbusiness.industryGoserelin AcetateAntagonistObstetrics and GynecologyLuteinizing HormoneLong actingEndocrinologyTreatment OutcomeReproductive MedicineCetrorelixGoserelinFemaleFollicle Stimulating Hormone Humanbusinesshormones hormone substitutes and hormone antagonistsTranssexualismmedicine.drugFertility and sterility
researchProduct

β2 long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD

2012

AbstractWe quantified TGF-β1 and acetylcholine (ACh) concentrations in induced sputum supernatants (ISSs) from 18 healthy controls (HC), 22 healthy smokers (HS) and 21 COPDs. ISSs from HC, HS and COPD as well as rhTGF-β1 were also tested in neutrophil adhesion and in mAChR2, mAChR3 and ChAT expression experiments in human bronchial epithelial cells (16-HBE). Finally, we evaluated the effects of Olodaterol (a novel inhaled β2-adrenoceptor agonist) and Tiotropium Spiriva®, alone or in combination, on neutrophil adhesion and mAChRs and ChAT expression in stimulated 16-HBE. The results showed that 1) TGF-β1 and ACh concentrations are increased in ISSs from COPD in comparison to HC and HS, and T…

Agonistmedicine.medical_specialtymedicine.drug_classchemistry.chemical_compoundInternal medicineTGF-β1Anticholinergic drugMuscarinic acetylcholine receptormedicineCOPDReceptorMolecular BiologyBeta2 long actingCOPDChemistryOlodaterolTiotropium bromidemedicine.diseaserespiratory tract diseasesEndocrinologyMolecular MedicineNeutrophilic inflammationBronchoconstrictionmedicine.symptomAcetylcholinemedicine.drugBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

Domain decomposition in the symmetric boundary element analysis

2002

Recent developments in the symmetric boundary element method (SBEM) have shown a clear superiority of this formulation over the collocation method. Its competitiveness has been tested in comparison to the finite element method (FEM) and is manifested in several engineering problems in which internal boundaries are present, i.e. those in which the body shows a jump in the physical characteristics of the material and in which an appropriate study of the response must be used. When we work in the ambit of the SBE formulation, the body is subdivided into macroelements characterized by some relations which link the interface boundary unknowns to the external actions. These relations, valid for e…

Applied MathematicsMechanical EngineeringNumerical analysisBoundary element analysisMathematical analysisComputational MechanicsOcean EngineeringDomain decomposition methodsFinite element methodComputational MathematicsComputational Theory and MathematicsCollocation methodCompatibility (mechanics)JumpBoundary element Symmetric boundary element method Macroelements SubstractingSettore ICAR/08 - Scienza Delle CostruzioniBoundary element methodMathematicsComputational Mechanics
researchProduct

Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophreniaspectrum disorders: Findings f…

2020

This study, based on the 'Servizi Territoriali Associati per la Ricerca' (STAR) Network Depot Study nationwide baseline data, explored whether individual symptoms severity and clusters might influence the prescription of paliperidone palmitate 1-month (PP1M) vs. aripiprazole monohydrate. The Brief Psychiatric Rating Scale (BPRS) was used to assess psychopathology and relevant symptoms clusters. Drug Attitude Inventory, 10 items, was used to test attitude towards medications. Adherence to treatments was rated according to the Kemp seven-point scale. We assessed for eligibility 451 individuals and, among them, we included 195 subjects (n = 117 who started PPM1 and n = 78 aripiprazole monohydr…

Aripiprazole monohydrate; Long-acting injectable antipsychotics; Paliperidone palmitate; Schizophrenia; Adult; Antipsychotic Agents; Aripiprazole; Female; Health Knowledge Attitudes Practice; Humans; Male; Medication Adherence; Paliperidone Palmitate; Practice Patterns Physicians'; Schizophrenia; Schizophrenic Psychology; Young AdultAdultMaleLong-acting injectable antipsychoticmedicine.medical_specialtyHealth Knowledge Attitudes Practicemedicine.medical_treatmentAripiprazole monohydrate Long-acting injectable antipsychotics Paliperidone palmitate SchizophreniaAripiprazolePractice PatternsLong-acting injectable antipsychoticsMedication Adherence03 medical and health sciencesYoung Adult0302 clinical medicineAripiprazole monohydrate; Long-acting injectable antipsychotics; Paliperidone palmitate; SchizophreniaInternal medicineBrief Psychiatric Rating ScalemedicineHumansPharmacology (medical)Practice Patterns Physicians'AntipsychoticSettore MED/25 - PsichiatriaPaliperidone PalmitatePaliperidone palmitatePracticePhysicians'business.industryHealth KnowledgeAripiprazole monohydratemedicine.disease030227 psychiatryPsychiatry and Mental healthSchizophreniaAttitudesPropensity score matchingSchizophreniaObservational studyAripiprazoleFemaleSchizophrenic Psychologybusiness030217 neurology & neurosurgerymedicine.drugPsychopathologyAntipsychotic Agents
researchProduct

Determining the dark matter mass with DeepCore

2013

Cosmological and astrophysical observations provide increasing evidence of the existence of dark matter in our Universe. Dark matter particles with a mass above a few GeV can be captured by the Sun, accumulate in the core, annihilate, and produce high energy neutrinos either directly or by subsequent decays of Standard Model particles. We investigate the prospects for indirect dark matter detection in the IceCube/DeepCore neutrino telescope and its capabilities to determine the dark matter mass.

AstrofísicaNuclear and High Energy PhysicsLarge Underground Xenon experimentAstrophysics::High Energy Astrophysical PhenomenaDark matterScalar field dark matterFOS: Physical sciencesAnnihilationAstrophysicsAstrophysics::Cosmology and Extragalactic Astrophysics7. Clean energy01 natural sciencesHigh Energy Physics - Phenomenology (hep-ph)Baryonic dark matter0103 physical sciencesWarm dark matter010306 general physicsLight dark matterPhysicsHigh Energy Astrophysical Phenomena (astro-ph.HE)Cosmologia010308 nuclear & particles physicsHot dark matterAstronomyDetectorsHigh Energy Physics - Phenomenology13. Climate actionWeakly interacting massive particlesHigh Energy Physics::ExperimentAstrophysics - High Energy Astrophysical Phenomena
researchProduct

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1…

2012

OBJECTIVE We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%. RESEARCH DESIGN AND METHODS In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run-in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks’ open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued unchanged treatment (observational arm). The primary end point was A1C change bet…

Blood GlucoseMaleEXENATIDEendocrine system diseasesdiabetes liraglutide metfortmin hypoglycemiaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType 2 diabetesTHERAPYGastroenterologyMELLITUSInsulin DetemirGlucagon-Like Peptide 1GLYCEMIC CONTROLOriginal ResearchInsulin detemirAged 80 and overClinical Care/Education/Nutrition/Psychosocial ResearchTREATED PATIENTSMiddle AgedMetforminMetforminNPH INSULINInsulin Long-ActingFemaleLife Sciences & Biomedicinehormones hormone substitutes and hormone antagonistsmedicine.drugAdultmedicine.medical_specialtyPARALLEL-GROUPAdolescentmedicine.drug_classHypoglycemiaEndocrinology & MetabolismDiabetes mellitusInternal medicineInternal MedicinemedicineHumansHypoglycemic AgentsCOMBINATIONAgedGlycated HemoglobinAdvanced and Specialized NursingScience & TechnologyLiraglutidebusiness.industryInsulin26-WEEKnutritional and metabolic diseasesLiraglutideEFFICACYmedicine.diseaseSulfonylureaEndocrinologyDiabetes Mellitus Type 2business
researchProduct